These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24170770)

  • 21. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
    Cheung WY; Shi Q; O'Connell M; Cassidy J; Blanke CD; Kerr DJ; Meyers J; Van Cutsem E; Alberts SR; Yothers G; Sargent DJ;
    Clin Colorectal Cancer; 2013 Sep; 12(3):179-87. PubMed ID: 23810482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
    Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
    Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence and cancer-specific death after adjuvant chemotherapy for Stage III colon cancer.
    Chapuis PH; Bokey E; Chan C; Keshava A; Rickard MJFX; Stewart P; Young CJ; Dent OF
    Colorectal Dis; 2019 Feb; 21(2):164-173. PubMed ID: 30253025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Higuera O; Burgos E; Ramos D; Calatrava A; Andrada E; López R; Moreno V; Madero R; Cejas P; Feliu J
    Ann Oncol; 2014 Feb; 25(2):398-403. PubMed ID: 24351404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.
    de Oca J; Azuara D; Sanchez-Santos R; Navarro M; Capella G; Moreno V; Sola A; Hotter G; Biondo S; Osorio A; Martí-Ragué J; Rafecas A
    Int J Colorectal Dis; 2008 Jan; 23(1):21-7. PubMed ID: 17805550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
    Szkandera J; Pichler M; Absenger G; Stotz M; Weissmueller M; Samonigg H; Asslaber M; Lax S; Leitner G; Winder T; Renner W; Gerger A
    Clin Cancer Res; 2014 Mar; 20(6):1687-97. PubMed ID: 24470513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
    Blons H; Emile JF; Le Malicot K; Julié C; Zaanan A; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Nørgård-Petersen L; Van Cutsem E; Lepage C; Zawadi MA; Salazar R; Laurent-Puig P; Taieb J
    Ann Oncol; 2014 Dec; 25(12):2378-2385. PubMed ID: 25294886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.
    Sebio A; Gerger A; Matsusaka S; Yang D; Zhang W; Stremitzer S; Stintzing S; Sunakawa Y; Yamauchi S; Ning Y; Fujimoto Y; Ueno M; Lenz HJ
    Pharmacogenet Genomics; 2015 Jan; 25(1):30-7. PubMed ID: 25379721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
    Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
    JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells.
    Sugimachi K; Yokobori T; Iinuma H; Ueda M; Ueo H; Shinden Y; Eguchi H; Sudo T; Suzuki A; Maehara Y; Mori M; Mimori K
    Ann Surg Oncol; 2014 Oct; 21(11):3680-90. PubMed ID: 24217791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
    Baretti M; Rimassa L; Personeni N; Giordano L; Tronconi MC; Pressiani T; Bozzarelli S; Santoro A
    Clin Colorectal Cancer; 2018 Sep; 17(3):e489-e498. PubMed ID: 29650416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.